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We synthesized evidence from the POPI sexual-health cohort 
study and estimated that 4.9% (95% credible interval, .4–14.1%) 
of Mycoplasma genitalium infections in women progress to 
pelvic inflammatory disease versus 14.4% (5.9–24.6%) of chla-
mydial infections. For validation, we predicted PID rates in 4 
age groups that agree well with surveillance data.
Keywords.  Mycoplasma genitalium; pelvic inflammatory 
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Increasing evidence indicates that Mycoplasma genitalium 
(Mgen) is a sexually transmitted infection that can lead to pelvic 
inflammatory disease (PID) [1]. To develop optimal testing and 
treatment guidelines for Mgen control, it is necessary to un-
derstand its natural history and the population burden of as-
sociated disease, about which there is currently considerable 
uncertainty [2].
The Prevention of Pelvic Infection (POPI) Study from England 
[3, 4] is the only published cohort study of PID incidence in 
women with and without Mgen and Chlamydia trachomatis (Ct) 
infection. We analyzed data from POPI to estimate, first, the pro-
portion of Mgen infections that were associated with progres-
sion to PID; second, the proportion of the total PID burden that 
was attributable to Mgen; and third, the PID rate associated with 
Mgen in women aged 16–44 years in England.
METHODS
The POPI study [3, 4] was primarily a trial of chlamydia 
screening, recruiting female students aged 27 years or younger 
in London, England, 2004–2006. Women provided self-taken 
vaginal swabs for chlamydia testing and were randomly allo-
cated to testing either immediately (screened group) or after 
12 months’ storage (deferred screening controls). In a retrospec-
tive substudy, Mgen infection was diagnosed in women from 
both randomization groups using an in-house nucleic acid am-
plification test [4] and stored swabs from baseline and obtained 
by postal follow-up 11–32 months later (median, 16 months). 
A total of 2378 women had baseline swabs tested for Mgen, and 
900 (38%) had follow-up swabs tested. Genitourinary doctors 
used medical records and participant questionnaires to diag-
nose possible PID cases in the year following enrollment. Data 
on PID therefore include all cases within 1 year, not only those 
that were ongoing at the time of follow-up. Asymptomatic cases 
of PID could not be identified. We used data from both arms of 
the trial, since there was no difference in participant manage-
ment during the follow-up period.
As Ct is an important cause of PID [5] we devised a mathemat-
ical model to account for PID due to both Ct and Mgen. In the 
model, women are in 1 of 4 states: (1) infected with neither Ct nor 
Mgen; (2) infected with Ct, uninfected with Mgen; (3) uninfected 
with Ct, infected with Mgen; or (4) infected with both Ct and 
Mgen. Women move between states according to a susceptible-
infected-susceptible (SIS) model of natural history, with per-capita 
infection rates αSC (Ct) and αSM  (Mgen) and recovery rates αCS  
(Ct) and αMS (Mgen). Neither infection affects the acquisition or 
recovery rate of the other. There is a “background” rate of devel-
oping PID, αSP, and rates attributable to Ct and Mgen infection, 
αCP and αMP respectively. The model is illustrated in Figure 1A, 
and full details are given in the Supplementary Information, 
Methods (Part 1) and Supplementary Figure 1. The prevalences 
of Ct and Mgen are shown by the following equations:
Steady-state Ct prevalence = C∗ =
αSC
αCS + αSC
Steady-state Mgen prevalence = M∗ =
αSM
αMS + αSM
The probability that a woman who was infected with Mgen at 
time zero is also infected at time t is:
αSM
αMS + αSM
+
αMS
αMS + αSM
e−(αMS+αSM) t
We conducted a Bayesian evidence synthesis using our model, 
with uninformative Gamma (1,2) priors on all parameters—ex-
cept for αCS , which had a normally distributed prior, reflecting 
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knowledge of the clearance rate of untreated Ct infection [5]. 
The likelihood was calculated based on 7 pieces of data from 
the POPI study, which are the numbers of women who were 
initially
 1. Ct infected (137/2377);
 2. Mgen infected (78/2378);
 3. Mgen infected, and who were also infected when followed 
up, after a median time of 16 months (7/27);
 4. Ct uninfected and who developed PID over the year fol-
lowing enrollment (31/2114);
 5. Ct infected and who developed PID over the year following 
enrollment (7/70);
 6. Mgen uninfected and who developed PID over the year fol-
lowing enrollment (36/2169); and
 7. Mgen infected and who developed PID over the year fol-
lowing enrollment (3/77).
We sampled from the posterior parameter distributions using a 
Markov chain Monte Carlo (MCMC) algorithm, implemented 
in the Stan software (Stan Development Team). The code 
used for analysis is available at https://github.com/joanna-
lewis/mgen_evidence_synthesis. We generated 75 000 sam-
ples, 15 000 from each of 5 chains, following a 5000-sample 
warm-up period.
For each sampled parameter set we calculated the proportion 
of women acquiring Mgen or Ct infection who would be ex-
pected to develop PID:
αMP
αMP + αMS
for Mgen and
αCP
αCP + αCS
for Ct,
and the proportion of PID in the POPI population that was at-
tributable to Ct and Mgen infection:
M∗αMP
M∗αMP + C∗αCP + αSP
for Mgen and
C∗αCP
M∗αMP + C∗αCP + αSP
for Ct.
Figure 1. A, Mathematical model for Ct and Mgen infection and recovery, used to synthesize evidence. Women move between states according to a susceptible-infected-
susceptible (SIS) model of natural history, with per-capita infection rates alphaSC (Ct) and alphaSM (Mgen) and recovery rates alphaCS (Ct) and alphaMS (Mgen). Neither in-
fection affects the acquisition or recovery rate of the other. There is a “background” rate of developing PID, alphaSP, and rates attributable to Ct and Mgen infection, alphaCP 
and alphaMP respectively. B, PID rates per 100 000 women, predicted by our model using Ct and Mgen prevalence in 4 age groups in Natsal-2 (Ct) and Natsal-3 (Mgen). The 
prediction includes a correction to allow for the fact that only women with PID who are diagnosed (estimated to be 55% of those with symptoms; see Methods) are recorded 
in surveillance data. Point markers and error bars show posterior medians and 95% credible intervals, adjusted for the fraction of cases presenting for medical care; num-
bers are given above the plot. Circles indicate all cases, upward-pointing triangles Ct-attributable cases, and downward-pointing triangles Mgen-attributable cases. Density 
plots around the all-cause predictions show the sampled posterior distributions. Dashed lines indicate upper and lower bounds for PID rate observed in surveillance in 2002 
reported by Price et al [5], adjusted for the proportion of women who were sexually active in each age group. Abbreviations: Ct, Chlamydia trachomatis; Mgen, Mycoplasma 
genitalium; Natsal, National Survey of Sexual Attitudes and Lifestyles; PID, pelvic inflammatory disease; +, positive; –, negative.
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We also used our model and Ct and Mgen prevalence data from 
the National Survey of Sexual Attitudes and Lifestyles (Natsal) 
studies [6, 7] to predict PID rates in 4 age groups of women in 
England. As POPI recruited in 2004–2006, which was during 
the early stages of the roll-out (from 2003 to 2008) of England’s 
National Chlamydia Screening Program, we used the Natsal-2 
Ct prevalence data because they reflect the situation at that 
time. Mycoplasma genitalium prevalence was estimated only by 
Natsal-3, but it seems likely that prevalence had remained rela-
tively constant over the preceding years because there was little 
change in sexual behavior between the Natsal-2 and Natsal-3 
surveys, and no specific intervention against Mgen prior to or 
at the time of either survey.
In POPI, only 21 of the 38 PID cases diagnosed (55%) were 
reported as PID by the participant or her general practitioner 
(GP). We therefore adjust our predicted PID rates by multi-
plying by a reporting fraction sampled from a Beta (22,18) dis-
tribution (mean, 55%; reflecting the observed proportion of 
cases reported). Following Price et  al [5], we compared these 
adjusted predictions to 2002 PID surveillance data from geni-
tourinary medicine (GUM) clinics, GPs, and hospital episode 
statistics, taking the sum of all 3 sources as an upper bound and 
the number in GUM clinics plus the larger of the numbers from 
GPs and hospitals as a lower bound. These were used to calcu-
late PID rates per 100 000 sexually active women, taking the 
proportion of each age group who were sexually active from 
Natsal-2.
RESULTS
We found that 4.9% (95% credible interval, .4–14.1%) of Mgen 
infections progress to PID, compared with 14.4% (5.9–24.6%) 
of Ct infections. We estimated that 9.4% (.8–28.8%) of PID 
in the POPI population was attributable to Mgen infection, 
37.4% (14.9–63.9%) to Ct, and the remaining 51.9% (21.4–
77.8%) to other causes. The posterior distributions inferred 
for each of the model parameters, for the percentages of each 
infection that progress to PID, and for the percentage of PID 
attributable to Mgen, Ct, and other causes, are summarized 
in the Supplementary Information (Supplementary Table 1; 
Supplementary Figures 2 and 3).
Figure 1B shows PID rates predicted by the model, based on 
Ct and Mgen prevalence observed in women in Natsal, in 4 age 
groups. After accounting for the proportion of each age group 
who are sexually active and the proportion of PID cases that are 
reported, predictions match the observed data well. The model 
reproduces the decrease in PID rates with age, which was due 
mainly to the lower Ct prevalence in older women. In younger 
women, more PID was attributable to Ct than to Mgen. In older 
age groups the amount attributable to each infection was sim-
ilar, because Mgen prevalence was similar across age groups [7], 
whereas Ct prevalence decreased with age [8].
DISCUSSION
We have performed the first synthesis of multiple types of data 
to estimate the PID burden associated with Mgen. Using data 
from a single study enabled us to compare the incidence of PID 
associated with Mgen and Ct in a self-consistent manner: we 
found that, in this population, the percentage of infections that 
progressed was substantially lower for Mgen than Ct. Our esti-
mate of the proportion of PID in the study population that was 
attributable to Ct infection (37.4%; 14.9–63.9%) is comparable 
to other estimates made using several different methods [5], 
providing confidence in our method and our estimate of the 
proportion attributable to Mgen (9.4%; .8–28.8%).
Our estimate of 4.9% (.4–14.1%) of Mgen infections leading 
to PID is consistent with, and more precise than, the 7.1% 
(.2–33.9%) of women with incident infections who were diag-
nosed with PID in another observational study [9], although 
that study’s design only counted women with PID at the time of 
Mgen diagnosis and would therefore miss women whose PID 
episodes had ended or who would have developed PID if their 
infection had not been detected and treated. Our estimate is sub-
stantially lower than the 12.2% of Mgen-positive women who 
developed PID following termination of pregnancy [10]. This 
disparity is also seen with Ct, with 63% of Ct-positive women 
developing PID following surgical termination of pregnancy 
[11], compared with a 17.1% risk inferred by synthesizing evi-
dence from several studies, which also adjusted for women with 
PID not presenting to care [5]. These estimates using the POPI 
study highlight the importance of providing young women with 
information on PID and access to high-quality care, as approx-
imately 45% of women with PID were not reported in routine 
statistics either because of underreporting, incorrect diagnosis, 
or because they had symptoms associated with PID but did not 
visit a healthcare professional for assessment.
Compared with Ct, we have estimated that Mgen has a 
lower chance of progression to PID as well as a lower preva-
lence in young women [7], both factors that tend to reduce the 
cost-effectiveness of screening. Our findings support British 
Association for Sexual Health and HIV (BASHH) guidelines 
[12] advising Mgen testing in women presenting with PID but 
not widespread Mgen screening, as this is unlikely to be effec-
tive in reducing PID in young women and is certainly less im-
portant than Ct screening.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, so 
questions or comments should be addressed to the corresponding author.
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